Science Explorer Back to mapMap
Institution · Zymeworks (Canada)

Most cited papers from Zymeworks (Canada)

What are the most cited papers from Zymeworks (Canada)?

The most cited paper from Zymeworks (Canada) is "Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study" (James J. Harding et al., 2023), with 282 citations. Next come "Development of a quantitative mass spectrometry multi-attribute method for characterization, quality control testing and disposition of biologics" (231) and "The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development" (227).

Showing 50 of 75 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study James J. Harding et al. · The Lancet Oncology Open access 2 Jun 2023 282
2 Development of a quantitative mass spectrometry multi-attribute method for characterization, quality control testing and disposition of biologics Richard S. Rogers, Nancy S. Nightlinger, Brittney Livingston et al. · mAbs Open access 17 Jul 2015 231
3 The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development Raffaele Colombo, Paolo Tarantino, Jamie R. Rich et al. · Cancer Discovery Open access 23 Oct 2024 227
4 Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study Funda Meric‐Bernstam et al. · The Lancet Oncology Open access 15 Nov 2022 198
5 The therapeutic window of antibody drug conjugates: A dogma in need of revision Raffaele Colombo, Jamie R. Rich · Cancer Cell Open access 13 Oct 2022 194
6 An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity Nina E. Weisser et al. · Nature Communications Open access 13 Mar 2023 182
7 The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial Jason J. Luke et al. · Nature Medicine Open access 19 Oct 2023 139
8 Improving biophysical properties of a bispecific antibody scaffold to aid developability Thomas Spreter von Kreudenstein, Eric Escobar-Carbrera, Paula I. Lario et al. · mAbs Open access 24 Jul 2013 125
9 Human Subtilase SKI-1/S1P Is a Master Regulator of the HCV Lifecycle and a Potential Host Cell Target for Developing Indirect-Acting Antiviral Agents Andrea D. Olmstead, Wolfgang Knecht, Ina Lazarov et al. · PLoS Pathogens Open access 5 Jan 2012 78
10 HERIZON-GEA-01: Zanidatamab + chemo ± tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma Josep M. Tabernero, Lin Shen, Elena Elimova et al. · Future Oncology Open access 24 Aug 2022 65
11 Structural elements in the flexible tail of the co-chaperone p23 coordinate client binding and progression of the Hsp90 chaperone cycle Maximilian M. Biebl, Abraham López, Alexandra Rehn et al. · Nature Communications Open access 5 Feb 2021 62
12 460MO Preliminary results from a phase I study using the bispecific, human epidermal growth factor 2 (HER2)-targeting antibody-drug conjugate (ADC) zanidatamab zovodotin (ZW49) in solid cancers Komal L. Jhaveri, Hyo Sook Han, Efrat Dotan et al. · Annals of Oncology Open access Sep 2022 58
13 Capicua regulates neural stem cell proliferation and lineage specification through control of Ets factors Shiekh Tanveer Ahmad, Alexandra D. Rogers, Myra J. Chen et al. · Nature Communications Open access May 2019 54
14 An Oncofetal Glycosaminoglycan Modification Provides Therapeutic Access to Cisplatin-resistant Bladder Cancer Roland Seiler et al. · European Urology Open access 11 Apr 2017 52
15 Structural basis of cell wall anchoring by SLH domains in Paenibacillus alvei Ryan J. Blackler, Arturo Lòpez-Guzmán, Fiona F. Hager‐Mair et al. · Nature Communications Open access Aug 2018 44
16 LC-MS characterization and purity assessment of a prototype bispecific antibody R. Jeremy Woods, Michael Hongwei Xie, Thomas Spreter von Kreudenstein et al. · mAbs Open access Jul 2013 37
17 Defluorination Capability of l ‐2‐Haloacid Dehalogenases in the HAD‐Like Hydrolase Superfamily Correlates with Active Site Compactness Peter W. Y. Chan, Nilmadhab Chakrabarti, Chris Ing et al. · ChemBioChem Open access 13 Oct 2021 36
18 Inhibition of Sebum Production with the Acetyl Coenzyme A Carboxylase Inhibitor Olumacostat Glasaretil David W. C. Hunt, Geoffrey C. Winters, Roger William Brownsey et al. · Journal of Investigative Dermatology Open access Mar 2017 35
19 Design and Evaluation of ZD06519, a Novel Camptothecin Payload for Antibody Drug Conjugates Mark E. Petersen et al. · Molecular Cancer Therapeutics Open access 13 Feb 2024 31
20 1380P Phase (Ph) II study of zanidatamab + chemotherapy (chemo) in first-line (1L) HER2 expressing gastroesophageal adenocarcinoma (GEA) Geoffrey Yuyat Ku, Elena Elimova, C.S. Denlinger et al. · Annals of Oncology Open access Sep 2021 31
21 Neuroprotective Effect of Asiatic Acid in Rat Model of Focal Embolic Stroke Ki Yong Lee, Ok‐Nam Bae, Shelley B. Weinstock et al. · Biological and Pharmaceutical Bulletin Open access 2014 30
22 CanDIG: Federated network across Canada for multi-omic and health data discovery and analysis Lewis Jonathan Dursi et al. · Cell Genomics Open access Nov 2021 29
23 Characterization of a drug-targetable allosteric site regulating vascular endothelial growth factor signaling Katherine M. Thieltges, Dragana Avramović, Chayne L. Piscitelli et al. · Angiogenesis Open access 3 Mar 2018 23
24 Investigation of the Binding of a Carbohydrate‐Mimetic Peptide to its Complementary Anticarbohydrate Antibody by STD‐NMR Spectroscopy and Molecular‐Dynamics Simulations Monica G. Szczepina, Dustin W. Bleile, Bernardine M. Pinto · Chemistry - A European Journal 26 Aug 2011 21
25 Burkitt lymphoma expresses oncofetal chondroitin sulfate without being a reservoir for placental malaria sequestration Mette Ø. Agerbæk et al. · International Journal of Cancer Open access 20 Dec 2016 20
26 Incomplete transcriptional dosage compensation of chicken and platypus sex chromosomes is balanced by post-transcriptional compensation Nicholas C. Lister, Ashley Monique Milton, Hardip R. Patel et al. · Proceedings of the National Academy of Sciences Open access 29 Jul 2024 16
27 Safety, anti-tumour activity, and biomarker results of the HER2-targeted bispecific antibody ZW25 in HER2-expressing solid tumours F. Meric-Bernstam, D. Hanna, M. Beeram et al. · Annals of Oncology Open access Oct 2019 16
28 Protein engineering and the use of molecular modeling and simulation: The case of heterodimeric Fc engineering Thomas Spreter von Kreudenstein, Paula I. Lario, Surjit B. Dixit · Methods 6 Nov 2013 15
29 Translational PK/PD framework for antibody-drug conjugates to inform drug discovery and development Michael Z. Liao, Douglas D. Leipold, Shang‐Chiung Chen et al. · Xenobiotica Open access 13 May 2024 13
30 WaterLOGSY NMR Experiments in Conjunction with Molecular‐Dynamics Simulations Identify Immobilized Water Molecules That Bridge Peptide Mimic MDWNMHAA to Anticarbohydrate Antibody SYA/J6 Monica G. Szczepina, Dustin W. Bleile, Johannes Müllegger et al. · Chemistry - A European Journal 2 Sep 2011 13
31 Multivalent IgM scaffold enhances the therapeutic potential of variant-agnostic ACE2 decoys against SARS-CoV-2 Meghan M. Verstraete, Florian Heinkel, Janessa Li et al. · mAbs Open access 25 May 2023 12
32 Enhancing screening, brief intervention, and referral to treatment among socioeconomically disadvantaged patients: study protocol for a knowledge exchange intervention involving patients and physicians Ginetta Salvalaggio, Kathryn A. Dong, Christine Vandenberghe et al. · BMC Health Services Research Open access 22 Mar 2013 12
33 Managed Architecture of Existing Code as a Practical Transition Towards MDA Nikolai Mansurov, Djenana Campara · Lecture notes in computer science Conference paper 2005 12
34 Generation and structure-activity relationships of novel imidazo-thienopyridine based TLR7 agonists: application as payloads for immunostimulatory antibody drug-conjugates Michael G. Brant, Graham A. E. Garnett, Joy Guedia et al. · Bioorganic & Medicinal Chemistry Letters Open access 20 May 2023 11
35 Population pharmacokinetics of zanidatamab, an anti-HER2 biparatopic antibody, in patients with advanced or metastatic cancer Jeffrey R. Proctor, Elaina M. Gartner, Todd E. Gray et al. · Cancer Chemotherapy and Pharmacology 14 Sep 2022 11
36 Safety, anti-tumour activity, and biomarker results of the HER2-targeted bispecific antibody ZW25 in HER2-expressing solid tumours Do‐Youn Oh, Erika Paige Hamilton, Diana L. Hanna et al. · Annals of Oncology Open access Nov 2019 11
37 The Crystal Structure of the Active Form of the C-Terminal Kinase Domain of Mitogen- and Stress-Activated Protein Kinase 1 Margarita L. Malakhova, Igor D’Angelo, Hong Gyum Kim et al. · Journal of Molecular Biology Open access 10 Apr 2010 10
38 Asymmetric Fc Engineering for Bispecific Antibodies with Reduced Effector Function Eric Escobar-Cabrera, Paula I. Lario, Jason Baardsnes et al. · Antibodies Open access 16 May 2017 9
39 Designed Human Serum Hyaluronidase 1 Variant, HYAL1ΔL, Exhibits Activity up to pH 5.9 Stephan Reitinger, Johannes Müllegger, Brigitte Greiderer et al. · Journal of Biological Chemistry Open access 29 May 2009 9
40 Beyond the Guided Missile Paradigm: Embracing the Complexity of Antibody-Drug Conjugates Matthew Vogel, Raffaele Colombo, Paolo Tarantino · Journal of Clinical Oncology 17 Sep 2025 7
41 ZymePackNet: rotamer-sampling free graph neural network method for protein sidechain prediction Abhishek Mukhopadhyay, Amit Kadan, Benjamin McMaster et al. · bioRxiv (Cold Spring Harbor Laboratory) PreprintOpen access 6 May 2023 6
42 Incomplete transcriptional dosage compensation of vertebrate sex chromosomes is balanced by post-transcriptional compensation Nicholas C. Lister, Ashley Monique Milton, Hardip R. Patel et al. · bioRxiv (Cold Spring Harbor Laboratory) PreprintOpen access 24 Feb 2023 6
43 Facile assembly of 1,5-diazocan-2-ones via cyclization of tethered sulfonamides to cyclopropenes Jonathon P. Matheny, Pavel M. Yamanushkin, Peter A. Petillo et al. · RSC Advances Open access 2020 6
44 ZW38, a Novel Azymetric Bispecific CD19-Directed CD3 T Cell Engager Antibody Drug Conjugate with Controlled T Cell Activation and Improved B Cell Cytotoxicity Gordon Ng, Thomas Spreter, Rupert Hugo Davies et al. · Blood 2 Dec 2016 6
45 Computer-assisted design of industrial enzymes The resurgence of rational design and in silico mutagenesis John Vieceli, Johannes Müllegger, Ali Mostafa Tehrani · Industrial Biotechnology Dec 2006 6
46 Structure–Activity Relationships of Bis-Intercalating Peptides and Their Application as Antibody–Drug Conjugate Payloads Mark E. Petersen, Michael G. Brant, Manuel Lasalle et al. · Journal of Medicinal Chemistry 12 Jun 2023 5
47 Engineering a pure and stable heterodimeric IgA for the development of multispecific therapeutics Florian Heinkel, Meghan M. Verstraete, Siran Cao et al. · mAbs Open access 7 Nov 2022 5
48 AlbuCORE: an albumin-based molecular scaffold for multivalent biologics design Mário Sanches, Igor D’Angelo, Maria Isabel Jaramillo et al. · mAbs Open access 2020 5
49 Ubisol-AquaTM: Coenzyme Q10 Prevents Antiretroviral Toxic Neuropathy in an In Vitro Model Catherine Louise Cherry, Masqura Mobarok, Steve L Wesselingh et al. · Current HIV Research Apr 2010 5
50 Lymphocyte-derived cholinergic circuits modulate germinal center output and B cell activation Duygu Nechanitzky, Logan K. Smith, Robert Nechanitzky et al. · Nature Immunology 24 Feb 2026 4

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.